title: Localization of the delta opioid receptor and corticotropin-releasing factor in the amygdalar complex: role in anxiety.
abstract: It is well established that central nervous system norepinephrine (NE) and corticotropin-releasing factor (CRF) systems are important mediators of behavioral responses to stressors. More recent studies have defined a role for delta opioid receptors (DOPR) in maintaining emotional valence including anxiety. The amygdala plays an important role in processing emotional stimuli, and has been implicated in the development of anxiety disorders. Activation of DOPR or inhibition of CRF in the amygdala reduces baseline and stress-induced anxiety-like responses. It is not known whether CRF- and DOPR-containing amygdalar neurons interact or whether they are regulated by NE afferents. Therefore, this study sought to better define interactions between the CRF, DOPR and NE systems in the basolateral (BLA) and central nucleus of the amygdala (CeA) of the male rat using anatomical and functional approaches. Irrespective of the amygdalar subregion, dual immunofluorescence microscopy showed that DOPR was present in CRF-containing neurons. Immunoelectron microscopy confirmed that DOPR was localized to both dendritic processes and axon terminals in the BLA and CeA. Semi-quantitative dual immunoelectron microscopy analysis of gold-silver labeling for DOPR and immunoperoxidase labeling for CRF revealed that 55 % of the CRF neurons analyzed contained DOPR in the BLA while 67 % of the CRF neurons analyzed contained DOPR in the CeA. Furthermore, approximately 41 % of DOPR-labeled axon terminals targeted BLA neurons that expressed CRF while 29 % of DOPR-labeled axon terminals targeted CeA neurons that expressed CRF. Triple label immunofluorescence microscopy revealed that DOPR and CRF were co-localized in common cellular profiles that were in close proximity to NE-containing fibers in both subregions. These anatomical results indicate significant interactions between DOPR and CRF in this critical limbic region and reveal that NE is poised to regulate these peptidergic systems in the amygdala. Functional studies were performed to determine if activation of DOPR could inhibit the anxiety produced by elevation of NE in the amygdala using the pharmacological stressor yohimbine. Administration of the DOPR agonist, SNC80, significantly attenuated elevated anxiogenic behaviors produced by yohimbine as measured in the rat on the elevated zero maze. Taken together, results from this study demonstrate the convergence of three important systems, NE, CRF, and DOPR, in the amygdala and provide insight into their functional role in modulating stress and anxiety responses.
authors.affiliation: Department of Pharmacology and Physiology, College of Medicine, Drexel University, 245 S. 15th Street, Philadelphia, PA, 19102, USA. Beverly.Reyes@drexelmed.edu.
authors.forename: Beverly A S
authors.initials: BAS
authors.lastname: Reyes
authors.affiliation: Department of Pharmacology and Physiology, College of Medicine, Drexel University, 245 S. 15th Street, Philadelphia, PA, 19102, USA.
authors.forename: J L
authors.initials: JL
authors.lastname: Kravets
authors.affiliation: Center for Substance Abuse Research, Department of Pharmacology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 19140, USA.
authors.forename: K L
authors.initials: KL
authors.lastname: Connelly
authors.affiliation: Center for Substance Abuse Research, Department of Pharmacology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 19140, USA.
authors.forename: E M
authors.initials: EM
authors.lastname: Unterwald
authors.affiliation: Department of Pharmacology and Physiology, College of Medicine, Drexel University, 245 S. 15th Street, Philadelphia, PA, 19102, USA.
authors.forename: E J
authors.initials: EJ
authors.lastname: Van Bockstaele
mesh_terms: D059331:Adrenergic Neurons / Q000166:cytology / Q000378:metabolism; D000679:Amygdala / Q000378:metabolism / Q000648:ultrastructure; D000818:Animals; D001007:Anxiety / Q000503:physiopathology*; D066272:Basolateral Nuclear Complex / Q000378:metabolism* / Q000648:ultrastructure*; D001549:Benzamides / Q000008:administration & dosage; D066274:Central Amygdaloid Nucleus / Q000378:metabolism* / Q000648:ultrastructure*; D003346:Corticotropin-Releasing Hormone / Q000378:metabolism*; D008297:Male; D009474:Neurons / Q000378:metabolism / Q000648:ultrastructure; D050484:Norepinephrine Plasma Membrane Transport Proteins / Q000378:metabolism; D010879:Piperazines / Q000008:administration & dosage; D051381:Rats; D017207:Rats, Sprague-Dawley; D017465:Receptors, Opioid, delta / Q000819:agonists / Q000378:metabolism*
chemical_list: D001549:Benzamides; D050484:Norepinephrine Plasma Membrane Transport Proteins; D010879:Piperazines; D017465:Receptors, Opioid, delta; C493226:Slc6a2 protein, rat; C088464:4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-N,N-diethylbenzamide; D003346:Corticotropin-Releasing Hormone
keywords: Amygdala; Corticotropin-releasing factor; Delta opioid receptor; Norepinephrine